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Abstract
It is of huge concern the possibility that at some point in the future we may face a new
pandemic involving a highly pathogenic virus due to our current preventive and treatment
options to fight this viral disease. The main reason for such limitations is the ability of the virus
to go over constant antigenic shifts and drifts on its viral surface proteins HA and NA. The
constant mutations that affect this virus cause the need of developing new vaccines for each
influenza season. Periodically, the World Health Organization (WHO) reports that around 10%
of the world population gets infected of which 25,000 to 50,000 persons die.
Our current research involves the study of the Influenza A Virus (IAV) viral proteins and the
effects that a novel tool created by our lab, the “ASL”, could have during viral infection. On the
work presented in this thesis we show that this tool has the ability to specifically attach to the
IAV NS1 protein and increase its levels of SUMOylation. With the implementation of this tool
we seek to provide information about the importance that the role of SUMOylation could have
on influenza viral infections. In addition, we seek to have a better understanding of the molecular
mechanisms by which SUMOylation regulates NS1’s function, therefore potentially leading to
the identification of new targets for the development of innovative anti-influenza therapies.
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Chapter 1. Introduction
Influenza viruses are virulent agents capable of causing serious acute respiratory infections,
belonging to the Orthomyxoviridae family, and subdivided into three types: A, B and C [1, 15].
All influenza types have the ability of produce infection in humans. The most pathogenic is type
A, which garners most of the current research; this strain has been the cause of the most
devastating pandemics in history. In contrast, influenza type B is less pathogenic than influenza
type A and causes mild seasonal epidemics, whereas influenza type C causes minor respiratory
symptoms and is considered of minimal pathogenicity in humans (15).
Every year influenza causes 250,000 to 500,000 deaths (WHO), and is responsible of
infecting roughly 10% of the world population. During the last 100 years, influenza has caused
four pandemics: the “Spanish influenza” (H1N1) in 1918, the “Asian influenza” (H2N2) in 1957,
the “Hong Kong” influenza (H3N2) in 1968, and the “Swine Flu” influenza (H1N1) in 2009. In
1918, the “Spanish flu” pandemic caused roughly 50 million deaths worldwide; this event was
arguably the most devastating global disaster caused by a viral agent (8).
Influenza is a viral disease that can be easily transmitted via inhalation, direct contact, or
spray due to its ability to travel via aerosol droplets (7, 16). Influenza causes acute respiratory
tract inflammation, high fever, body aches, and fatigue. However, serious complications of
influenza involve primary viral pneumonia, myositis and cardiac involvement, encephalopathy,
and encephalitis. The usefulness of the vaccines and antiviral drugs currently available to fight
this virus is limited because of the virus’ ability to constantly evolve. Current anti-influenza
vaccines are available in two different delivery forms through intramuscular injection or nasal
spray (7). However, the rapid changes undergone by the two major viral surface proteins,
hemagglutininn (HA) and neuraminidase (NA), triggers the need to reformulate the vaccine
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every new viral season. In addition, there are four antiviral drugs available on the market that
that have been specifically developed for the treatment of influenza infection. These drugs have
the ability to inhibit the action of specific viral proteins in the machinery of the virus (Fig. 1).
Rimantadine and amantadine are inhibitors of the matrix 2 (M2) ion channel and function by
inhibiting the acidification-dependent release of the viral ribonucleoprotein (vRNP). Zanamivir
and oseltamivir act as neuraminidase inhibitors preventing viral release upon viral budding. Both
types of antivirals have proven to be effective in preventing some of the most damaging effects
of influenza infection and have therapeutic and prophylactic action. However, resistance against
both types of antivirals is widespread among currently circulating human strains, therefore
limiting their clinical value and raising concerns that a new pandemic strain endowed with high
pathogenicity and resistance to current antivirals may arise with catastrophic consequences for
humanity (7).
In this proposal, we expand our studies on the effects that SUMOylation, a post-translational
modification, has on the IAV Non-Structural Protein 1 (NS1). In previous studies we have shown
that the NS1 protein appears to be the most SUMOylated IAV protein thus suggesting that this
post-translational modification could play an important regulatory role for NS1 function and, in
consequence, could constitute a therapeutic target for influenza viral infections. Here we present
the design of a novel tool, the Artificial SUMO Ligase (ASL) that has the ability to increase NS1
SUMOylation levels. Through the use of this tool, we aim to determine the importance of NS1
SUMOylation during viral infection and the role that SUMOylation could have on NS1’s ability
to downregulate the IFN response.
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1.1 Influenza viral life cycle
IAV is an enveloped virus with negative sense single stranded ribonucleic acid (-ssRNA)
that, in a very uncharacteristic way, carries out viral transcription and replication in the nucleus
of its host cell (1, 26). IAV causes infections in birds and mammals, and its genome consists of
eight segments of RNA that encode for 10 to 11 viral proteins, namely HA, NA, polymerase
basic protein 2 (PB2), polymerase basic protein 1 (PB1), polymerase acidic protein (PA),
nucleoprotein (NP), matrix proteins 1 and 2 (M1 and M2), NS1, nuclear export protein (NEP
formerly known as NS2), and polymerase basic protein 1 - F2 (PB1-F2) (1, 11, 25, 26). Each
protein has a unique function in the virus life cycle and all, except for PB1-F2 which is not
present in all viral strains are needed for proper viral multiplication (26).
The influenza virus life cycle begins when the virus attaches to the host cell plasma
membrane. The viral proteins that are responsible for driving the influenza viral particle to the
inside of the host cell are HA, NA, and M2. These viral proteins make up the surface of the
influenza viral particle and act in a set of molecular interactions with the plasma membrane of
the host cell (26). During influenza infection, HA gives the virion a spiky shape and makes
possible the binding of the viral particle to the sialic acid present on the surface of the host cell
membrane, facilitating its entrance to the host cell via receptor mediated endocytosis. Once in the
endocytic vesicle subsequent acidification of the endosome causes the opening of the M2 ion
channels which acts as a low pH-gated channel, thus leading the acidification of the viral
particle. This triggers the detachment of the viral ribonucleoprotein complexes (vRNPs) from the
M1 protein and the fusion of viral membrane with the endosomal membrane. The vRNPs which
are made of a complex of the viral proteins NP, PA, PB1 and PB2 associated to one vRNA gene
segment are then released into the cytoplasm of the host cell where they bind nuclear import
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factors which allow their entrance into the nucleus of the host cell (5, 26). Once the vRNPs
successfully enter the nucleus they initiate viral transcription. Transcription is possible through a
complex of the viral proteins PB1, PB2, and PA, best known as the viral RNA dependent RNA
polymerase (RdRp), and also requires NP. The synthesis of viral messenger RNA (mRNA) is
driven by a process called “cap-snatching”, in which the RdRp binds to host cell mRNA and
steals the 5’cap using it as a primer for mRNA synthesis (26). The result of transcription gives
rise to eight primary transcripts, where M and NS generate two alternative transcripts, one
corresponding to a spliced transcript and one corresponding to the unspliced full-length
transcript. Then, transcribed mRNAs are transported back to the cytoplasm where ribosomes
translate all mRNAs and produce new viral RNA-polymerase complexes which stimulate viral
genome replication to make new viral RNA (vRNA). In the meantime, HA, NA, and M2 proteins
enter the secretory pathway where they get glycosylated and are directed to the plasma
membrane. Newly synthesized RdRp, NP, M1, NS1, and NEP are transported back to the
nucleus, where they form the vRNPs that will be incorporated into new viral particles.
Importantly, M1 binds the newly synthesized negative strand RNA (-RNA) to shut down viral
mRNA synthesis and attaches NEP proteins to export progeny vRNPs out of the nucleus into the
cytoplasm. Meanwhile, NS1 deals with the interferon machinery in order to shut down the
function of specific antiviral sensors (Fig. 2) (7, 11). Lastly, the virion is assembled through an
initiate set of interactions established between M1, vRNPs, and the viral membrane proteins HA,
NA, and M2, resulting in the budding of new viral particles at the apical surface of the plasma
membrane. NA cleaves sialic acid receptors present in the plasma membrane to release the
infectious viral particle and infect other cells (Fig. 1) (7, 26).
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One key player in the whole viral cycle is NS1. NS1 shuts down the host cell's immune
system allowing the virus to freely propagate and cause infection (26). This protein constitutes
the main focus of this proposal, NS1 achieves this function by affecting mRNA processing,
binding and coating double stranded RNA (dsRNA), and affecting the protein effectors of the
interferon (IFN) response (1, 11) such as the cytoplasmic retinoic acid-inducible gene 1 (RIG-I),
protein kinase R (PKR), and 2'-5'oligoadenylate synthetase (OAS), as shown in Fig. 2 (11). RIGI has been identified as the Type I Interferon (IFN a/ß) cytoplasmic sensor that responds to
influenza infections (13, 24). In addition, upon RIG-I activation the nuclear factor kappa-lightchain-enhancer of activated B cells (NF-kB) and interferon regulatory factor 3 (IRF3) signaling
pathways get activated to stimulate the synthesis of interferon stimulated genes (ISGs), such as
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IFN ß, thus ensuring widespread viral control (2, 19). This subject is described in more detail in
the following section.

1.2 Interferon response and NS1
The cellular IFN response is best described as an intracellular immunological response
produced by mammalian cells when foreign pathogens try to attack them (7). Mammalian cells
comprise multiple cytoplasmic and plasma membrane receptors to recognize foreign pathogens
and act against them according to the type of DNA or RNA they own. When these receptors
recognize a foreign pathogen, a signaling cascade starts in the cellular system and affects specific
events in the pathogens’ life cycle. In the case of the life cycle of viral agents, IFN response can
act by inhibiting the virus binding and uncoating, transcription of mRNAs, replication of
genome, translation of proteins, or assembly and release of the virion (7). For this reason,
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influenza viral strains have already well identified the IFN receptor responsible of recognizing its
genome, known as tripartite motif 25 (TRIM25). Thus, influenza NS1 has the ability to directly
interact with TRIM25 and this prevents IFN response.
The most important classes of IFN are IFN a, ß, and g; these subdivide into two types that
correspond to IFN a/ß and Type II Interferons (IFN g) (7). IFN a/ß is the type of IFN that is
secreted from mammalian cells during viral infection and is present in all cells of the human
body. However, IFN g is very cell specific, this type of IFN is secreted by thymus-derived cells
(T cells), goes over specific conditions of activation, and responds to natural killer cells (4).
Cells possess a variety of extracellular and intracellular receptors specific to recognize and
attack bacteria, parasites, viruses, and fungi (4). For this reason, IFN is produced intracellularly
when a viral infection takes place and it is also present in small amounts in the extracellular fluid
(7). When ISGs are present in the extracellular fluid, the receptors present on the surface of the
uninfected cells have the ability to recognize ISGs. Thus, uninfected cells respond to ISGs
producing more of these genes to alert the surrounding cells that a viral infection is taking place.
Virus-infected cells activate the IFN pathway to produce ISGs with transcription factors IRF-3,
NF-kb, activating transcription factor 2 (ATF-2) and C-Jun. The IFN induction at the site of
infection is very rapid; it occurs within hours of infection and declines in less than 10 hours (7).
During viral infection, transcription factors get activated and stimulate human IFN-ß
transcription; unfortunately, IFN-ß transcription is only possible for a short period of time. Thus,
if the cell machinery fails to produce ISGs or does not posses IFN receptors it will not be
protected from viral infection (7).
For RNA viruses, there are specifically two types of intracellular pattern recognition
receptors (PRRs) that are responsible for ss-and-dsRNA recognition, Toll-Like receptors (TLRs)
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and RIG-I-like receptors (RLRs). TLRs 3, 8, 7 and 9 are present on the surface of intracellular
endosomes and are helpful in the cellular system by producing antiviral defenses (20). RIG-I is a
cytoplasmic sensor indispensable to control viral infection; it has the ability to activate
mitochondrial antiviral-signaling protein (MAVS). MAVS is needed to stimulate the signaling
cascade that makes possible the transcription of factors NF-kb and IRF-3 to produce ISGs (12).
The activation of RNA sensors like RIG-I is mediated by the recognition of pathogenassociated molecular patterns (PAMPs). RIG-I is a cytoplasmic sensor that specifically
recognizes RNA viruses (e.g. Flaviviridae, Paramyxoviridae, Orthomyxoviridae, and
Rhabdoviridae) (12). In the case of the influenza virus, this is an -ssRNA viral strain from the
Orthomyxoviridae family recognized by this cytosolic RNA helicase sensor “RIG-I” (Fig. 3).
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RIG-I activation starts when TRIM25 an ubiquitin E3 ligase recognizes RNA, by RNA
recognition, TRIM25 induces ubiquitination of RIG-I amino-terminus (N-terminus) caspase
recruitment domain (CARD). The ubiquitination of RIG-I is induced through a multimer
formation between TRIM25 and RIG-I. The multimer is formed when TRIM25 carboxy-terminal
SPRY domain adds ubiquitin (ub) to the CARDs of RIG-I. This ubiquitin side chain helps RIG-I
bind to the MAVS (also known as VISA, IPS-1, or Cardif), attached to a mitochondrion. After
RIG-I binds to MAVS, MAVS turns on the signaling cascade that leads to the activation of
transcription factors NF-kb and IRF-3, therefore producing type I IFN (12, 10).
During influenza infection, it has been shown that NS1 is the protein responsible for dealing
with the IFN system of the host cell directly affecting the machinery. When influenza attacks the
cellular system of the host cell, NS1 has the unique ability to directly interact with cellular
elements that are responsible for recognizing the PAMPs. As previously described, RIG-I is
specifically responsible for activating the signaling cascade against RNA viruses. Recent studies
have shown that NS1 directly interacts with TRIM25 a cytoplasmic sensor that as previously
described induces RIG-I ubiquitination to activate the IFN system. NS1 prevents the
ubiquitination of RIG-I when it directly interacts with TRIM25 and prevents the multimer
formation that makes possible the interaction between TRIM25 and RIG-I. The specific aminoacid sequence involved in NS1 binding to TRIM25 corresponds to Thereonine-LeucineGlutamic-Glutamic acid (Thr-Leu-Glu-Glu acid). As a result, of NS1 binding with TRIM25,
NS1 prevents IFN response and provokes viral infection (9, 10).
Thus, our study seeks to determine the importance of NS1 SUMOylation during viral
infection when it directly interacts with specific factors involved with the IFN system activation,
those being RIG-I and TRIM25.
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1.3 SUMOylation
Small Ubiquitin-Like Modifier (SUMO) is a post-translational protein modifier (21, 3). SUMO
has been identified as key player in regulating its target proteins activity, stability, cellular
localization, and protein-protein interactions (22). There are hundreds of SUMO targets that have
been characterized in recent research, most of these proteins are identified to reside in the
nucleus, their size is about 10 kiloDalton (kD), and their structure is tremendously related to the
three-dimensional structure of ubiquitin (21). Humans comprise four SUMO proteins in their
genome subdivided into SUMO 1 – SUMO 4 (21). These proteins do not reside in the same
places and have different functions; SUMO 1 – SUMO 3 can be found all over the human body,
in contrast with SUMO 4 which resides only in three specific organs of the human body: the
kidneys, lymph nodes, and spleen (21). There are the two main reasons for sub-diving SUMO
proteins into four paralogs; first the specificity of original activation (proteases that cleave the
SUMO protein) and second the direction in which SUMO-interacting motifs specifically bind
proteins (3). In addition, SUMO proteins 2 and 3 are more than 90% identical, therefore they are
known as SUMO2/3; in contrast with SUMO1 which is only 50% identical to SUMO2/3 (21).
SUMOylation consists of the formation of an isopeptide bond between the carboxy
terminus (C-terminus) glycine (Gly) residue of mature SUMO (i.e. modifier protein) and the
lysine (Lys) residue of its target protein (i.e. acceptor protein) (3, 6, 21). To activate the SUMO
pathway (also refered as SUMOylation pathway) the involvement of an enzymatic cascade is
necessary. This cascade is dependent on three different enzymes: E1 (activating enzyme), E2
(conjugating enzyme), and E3 (protein ligase) (21). In addition, the enzymatic cascade divides
into three stages that make the modification of a protein possible by SUMO.
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The SUMOylation pathway begins when the SUMO precursor matures; SUMO maturation
consists of sentrin-specific protease (SENP) cleavage to the C-terminus of SUMO. By SENP
cleavage, the SUMO precursor exposes its di-Gly motif that is required for proper recognition
and activation. Once the di-Gly motif at the C-terminus of SUMO is exposed, the first stage of
the SUMO pathway takes place, where an E1 enzyme activates the SUMO protein. The E1
enzyme is formed by an heterodimer composed of AOS1-UBA2 (i.e. SAE1-SAE2). And through
an adenosine triphosphate (ATP)-dependent reaction, the E1 enzyme heterodimer forms a
thioester bond with the di-Gly residue located at the C-terminus of SUMO, leading to SUMO
activation. Right after SUMO activation, the second stage takes places, here SUMO is
transferred from E1 to ubc9, known as E2 conjugating enzyme. The E2 enzyme also forms a
thioester bond with the di-Gly residue at the C-terminus of SUMO, but in this case the bond is
formed with a Cysteine (Cys) residue located in ubc9. Once the SUMO precursor is conjugated
with the E2 enzyme, the third stage begins, where SUMO ligation to the substrate (e.g. target
protein) is possible with the aid of an E3 ligase or an ubl-protein (in this case ubc9). The E3
ligase facilitates SUMO transfer from an E2 enzyme to an Ubiquitin H3CT E3 ligase. This last
stage forms an isopeptide bond between the carboxyl group on the di-Gly residue located at the
C-terminus of SUMO and the epsilon amino group on the Lys (K) residue of the target protein.
Thus, SUMOylation's role is to add SUMO proteins to its target proteins K residues (Fig. 4) (3,
21, 28).
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Given that influenza virus replicates in the nucleus, SUMOylation on influenza viral
proteins during viral infection is currently studied. As earlier mentioned, in previous studies we
have shown that the NS1 protein appears to be the most SUMOylated IAV protein. Due to this
reason, we find quite intriguing and important the need to define all the effects that
SUMOylation has on all of NS1 functions.
1.4 NS1 SUMOylation
Current findings suggest that SUMO substrates influence transcription and steps in the cell
cycle, which creates the issue that SUMOylation may be contributing to disease onset or
progression (6). Some research studies have shown that the SUMOylation of viral proteins
targets them to the nucleus where they take over the cell’s replication machinery, thus allowing
viral reproduction. In addition, there are numerous virus-encoded UBLs that exhibit de12	
  

ubiquitinating activity when expressed in host cells (14). A viral example for host UBL system
interference is the influenza B virus NS1 protein this inhibits conjugation of another UBL
induced by the IFN a/ß interferon-stimulated gene 15 (ISG15) (3).
Some other studies on IAV–NS1 protein have shown that its function is reliant on E2
enzyme. Interestingly, the assembly of ubc9 to NS1 could be an important key player in the viral
protein effect of down-regulation of cellular IFN ß response. Indeed, it also has been shown that
the E2 enzyme plays an important role in enhancing NS1 stability to rapidly reproduce IAV (17,
19). As described in the SUMOylation cycle, E2 (or ubc9) is the enzyme that is involved in the
transfer of SUMO to the acceptor target proteins making possible the interaction of SUMO and
the target protein through the Lysine residue that ubc9 posses (21).
Reports imply that the conjugating enzyme E2 (or ubc9) in the SUMOylation pathway is
responsible for transferring SUMO to all of its acceptor proteins. But the enzyme does not have
the ability to recognize any consensus sites with stable helical structures (21). However, in vitro
studies revealed the ability of ubc9 to directly SUMOylate target proteins. More interestingly,
some other studies had shown how viruses take advantage of cellular post-translational
modifications (3)
The actual role of ubc9 in NS1's ability to downregulate IFN responses has not yet been
fully described. In spite of this, we have designed a set of experiments to explore in more depth
and characterize the role of SUMOylation on NS1’s ability to downregulate cellular IFN
response, when it directly interacts with specific receptors of the IFN system. The results gain
from these studies will help us better understand the effects that SUMOylated NS1 has on the
IFN pathway during viral infection.
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Hypothesis
The main function of IAV–NS1 protein is to down-regulate host cell mRNA processing,
seize dsRNA and reduce IFN response (1, 9). NS1 protein directly interacts with the IFN sensors
responsible for the activation of the signaling cascade that induces IFN a/ß induction. The
induction of IFN a/ß is an immunological response produced by mammalian cells to control viral
infection and widespread. RIG-I is the IFN cytoplasmic sensor that gets ubiquitinated by
TRIM25 due to –ssRNA viral recognition. Once RIG-I gets ubiquitinated it activates the
mitochondrial sensor MAVS. Therefore, by MAVS activation the signaling cascade for IFN
induction starts leading to ISGs induction in order to invade viral pathogens (3, 19). In addition,
SUMO plays a key role in regulating its target protein activity, stability, cellular localization, and
protein-proteins interactions (18). With the information previously provided we formulated the
following hypothesis: increase in cellular SUMOylation will affect NS1’S ability to
downregulate the antiviral response. We found that NS1 SUMOylation is important in NS1’s
ability to down-regulate the cellular IFN a/ß response (14, 15). With the results obtained we were
able to expand our knowledge on the cellular mechanism by which NS1 triggers the IFN
response.

Specific Aims
1. Determine whether SUMO affects NS1’s ability to neutralize the interferon response
2. Further characterize the specificity of the Artificial SUMO Ligase (ASL) and its effect on
NS1
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Chapter 2. Determine whether SUMO affects NS1’s ability to neutralize the
IFN response
The main objective was to determine the role of SUMOylation on NS1’s ability to
neutralize IFN response. As previously described, NS1's main function is to downregulate IFN
response. We designed a set of experiments on behalf of previous work published by Rehwinkel
J. et al. where they described an effective way to induce IFN response by stimulating activation
of the RIG-I pathway using a reconstruction system of the vRNP of IAV (19). We used the same
system creating a replica of the vRNP, constituted of viral protein NP plus the three viral
proteins that conform the RdRp: PA, PB1, and PB2. Importantly, on this experiments we used a
set of plasmids that change NS1 functions: (1) NS1 in its native form (wt-NS1), (2) nonSUMOylatable form of NS1, here after referred as non-SUMO-NS1, prevents NS1 to
SUMOylate (NS1-K70AK219A), (3) a form of NS1 with infuse ubc9, this enhances NS1
SUMOylation levels (wt-ASL), and (4) NS1 with infuse ubc9, RNA-Binding Domain (RBD),
prevents the N-terminus region of NS1 to bind RNA (mut-ASL).
We started by conducting a bioassay mediated by a set of transfections on Hek293FT cells.
Here, we used a re-constitution of the vRNP using viral polymerase proteins: PA, PB1, and PB2
and NP driven by RNA Polymerase II (PolII) plus PB2 driven by RNA Polymerase I (PolI) to
have a functional vRNP. Reconstitution of the vRNP helped to stimulate the activation of the
RIG-I cytoplasmic sensor, where the IFN signaling cascade is activated and the pathway leads to
the induction of ISGs. The experiment was conducted in the following way: we made a set of
transfections with different combinations of the (1) vRNP with or without PolI PB2, (2) NS1 or
non-SUMO-NS1, and (3) wt-ASL or mut-ASL, to study the role of SUMOylation on NS1 and
the effect on its ability to downregulate the IFN induction. Two days after transfection, we
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harvested supernatants and collected total cell extracts. Then, we made dilutions of the
supernatants and added them to VERO cells to test for production and strength of IFN on each
experimental sample. VERO cells are known to be IFN deficient cells; therefore if ISGs were
produced on supernatants collected from Hek293FTs transfections, supernatants with ISGs were
expected activate IFN on VERO cells. Consequently, in order to test for induction of IFN on
VERO cells (note: supernatant was diluted in order to test the strength of this) we went ahead
and used a VSV-GFP reporter virus to infect them. This virus is a –ssRNA virus like influenza,
is extremely sensitive to IFN, and was a good reporter to use for our study. Therefore, we
expected to have inhibition of viral reproduction on the VERO cells if the supernatant, that was
used to stimulate them, had ISGs. Cells were incubated with the VSV-GFP virus for 8 hrs. After
incubation, we used three methods of collection to analyze our samples. We collected total cell
extracts, fixed, and analyzed cells by WB, flow cytometry, and confocal microscopy.

2.1 Results
As previously described, cells were fixed and transferred to flow cytometry tubes in order
to analyze for GFP fluorescence which indicated population of infected cells. Interestingly, our
results show that the method used to activate the IFN system worked because when the vRNP
was by itself, this inhibited replication of the VSV virus (in the absence of NS1). However, when
we tested the vRNP with the two different types of NS1: wt-NS1 or non-SUMOylatable NS1, it
was found that the produced IFN was reduced in significant values as shown in Fig 5. panel C
(bars 3 and 4).
Values obtained from the flow cytometry count for each experimental sample are shown
in Table 1. On the graph in Fig. 5 panel C. the sample that contained wt-NS1 was set as the
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100% inhibitor of IFN induction (first column left to right). When we compared wt-NS1 with the
non-SUMOylatable form of NS1 the inhibition percentage decreased ≈60% (second column
from left to right). Surprisingly, the wt-ASL plus wt-NS1 showed a significant increase of IFN
inhibition ≈60% when compared to wt-NS1 (third column from left to right) but when the mutASL plus wt-NS1 were tested for IFN inhibition, the IFN inhibition decreased to ≈20% when
compared to wt-NS1 (fourth column left to right). In addition, we went ahead and tested, by
western blot, our system to verify that the levels of NS1 SUMOylation were manipulated as it
was claimed on each sample. As shown in Fig. 5 panel A (lanes 5 and 6) a huge increase on
SUMOylated NS1 is visible due to the use of both forms of the ASL (wt-ASL and mut-ASL).
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In addition, to prove that the results obtained from the flow cytometer count were viable.
We decided to present our study by using confocal microscopy. To complete this part of the
study we went ahead and conducted the same VSV-GFP bioassay that was previously described.
However, in this case instead of collecting the cells extracts, we plated the VERO cells in a 96well plate, fixed, and analyzed by confocal microscopy. The cells were stained with DAPI to
show the total cell population and since they were infected with VSV-GFP virus, as previously
mentioned the infected cells expressed GFP, that make them glow green. As shown in Fig. 2
infection levels are altered on each sample. As previously stated our interest is to study the effect
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that the ASL has on NS1 when this viral protein prevents IFN induction. Our results are
consistent with the flow cytometer count. Where we show that increasing or decreasing
SUMOylation of NS1 is bad for NS1 ability to downregulate IFN induction. This idea has been
clearly shown by the results obtained on the flow cytometry as shown in Fig. 5 (panel 2 and 3)
and as well in the confocal microscopy study in Fig 6 (panel x and x) were the infection levels
increase or decrease according to the ASL usage with NS1.
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2.2 Discussion
On the work presented we showed two methods (flow cytometry and confocal
microscopy) in which we studied the importance of NS1 SUMOylation using our novel tool the
ASL. Here we were looking at the potential effects that this tool “the ASL” could have in two
forms of NS1: wt-NS1 and a non-SUMO-NS1. The ASL was used to enhance the SUMOylation
levels of NS1. As well a non-SUMOylatable form of NS1 was used to show the importance of
NS1 SUMOylation during viral infection. The importance of using two methods to analyze our
results was to prove that the study could be done in different ways. In addition, we show the
effectiveness of using the ASL as a system to increase SUMOylation levels of NS1 and the
importance SUMOylation during viral infection. Based in our results we conclude that using the
mut-ASL is not as effective as using the wt-ASL when enhancing NS1 SUMOylation. And that
increasing or decreasing the amount of SUMOylated NS1 negatively affect NS1’s ability to
inhibit IFN response. These results have helped us to expand our research based on the study of
the SUMOylation system on influenza.
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Chapter 3: Further characterize the specificity of the Artificial SUMO Ligase
(ASL) and its effect on NS1 SUMOylation
We have created an innovative tool that we refer to as the Artificial SUMO Ligase
(ASL); in our published work we have reported that this tool has the ability to enhance the
SUMOylation levels of IAV protein NS1. NS1 has two domains, known as RBD and the effector
domain (ED) separated by a flexible linker (amino acid residues 74 to 85). For this reason the
ASL consists of the connection of the RBD of NS1 (the first 73 amino acid) and the linker region
to SUMO-ubc9. The purpose of creating the ASL was to make possible the interaction of ubc9
with the Lysine residue K219 of NS1, thus enhancing SUMOylation of NS1 by dimerization of
the ASL with NS1 (Fig. 7). As shown in Fig. 7, the lysine residues present in both molecules are
the ones responsible for the dimerization of these. The next presented studies helped us to
characterize the functionality of the ASL by testing it’s: (1) effect, (2) specificity, and (3)
activity.
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3.1 Specificity of the ASL on NS1 SUMOylation
The ASL has the ability to enhance the SUMOylation level of NS1 protein when both
molecules the ASL and NS1 dimerize and come into close proximity. On this study we wanted to
determine if the length of the linker region that connects the two globular domains of the ASL
affects its function. As mentioned earlier, the ASL consists of a fusion of the linker region of
SUMO-ubc9 to the 73 RBD of NS1. For this reason, here we studied different length regions that
correspond to amino acid positions 73, 81, and 87 to observe: (1) the importance of the length of
the linker region, (2) if this affects the ASL specificity when it binds to NS1, (3) and if there is
any variation in the amount of SUMOylated NS1 produced.

3.1.2 Results
The main purpose of this study was to determine ASL specificity to NS1 and the
importance of the linker region on the ASL function. To test this we went ahead and conducted a
set of transfections on Hek293FT cells using combinations of the following plasmids: (1) wtNS1, (2) non-SUMO-NS1 (3) NS1 (1-73)-ubc9, (4) NS1 (1-81)-ubc9, and (5) NS1 (1-87)-ubc9.
The purpose of using plasmids 1 and 2 was to study the effect of the ASL in two types of NS1
(1) wt-NS1 and (2) non-SUMO-NS1. And plasmids 3, 4, and 5 were used to test three different
linker regions of NS1 fused to ubc9 that correspond to amino acid residues 73, 81, and 87. Then,
24 hours post-transfection, total cell extracts were collected, processed, and analyzed by
immunoblot.
This study clearly demonstrate the specificity of the ASL to NS1. As presented in Fig. 8
when we used the ASL on wt-NS1 panel A (lanes 4-7). This shows the ability of the ASL to
increase NS1 SUMOylation levels. In addition, we tested the ASL with a non-SUMOylatable
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form of NS1 (lanes 8-11). And is shown how the ASL has the ability to increase NS1
SUMOylation levels when the protein is not able to SUMOylate by itself. We also were
studying if the length of the linker region in the ASL affected its functionality. And as shown in
Fig 8 panel B the results of the percentage of SUMOylated NS1 were quantified. With this
results we found that as the linker region gets longer the percentage of SUMOylated NS1
increases. Based on these results, we claim that the length of the linker affects the activity of the
ASL on its ability to increase the percentage of SUMOylated NS1 but importantly it does not
affects its specificity with NS1.
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3.2 Activity of the ASL and its effect of NS1 SUMOylation
In our previous studies we have seen that there is an optimal amount of ASL needed in
order to enhance NS1 SUMOylation to its peak level. For that reason on this study we wanted to
determine the optimal amount of wt-ASL needed in order to SUMOylate IAV NS1 protein. This
study was done by conducting a set of transfections, using different amount of the wt-ASL with a
constant amount of wt-NS1.

3.2.2 Results
In this study we wanted to test the functionality of the wt-ASL to answer the question of
whether SUMOylation of NS1 was affected by the ratio of protein used when conducting
transfections of NS1 plus wt-ASL and whether the reaction that taking place was an enzymatic
action. Therefore, we conducted an experiment in which we transfected Hek293FT cells with:
(1) different concentrations of the wt-ASL (range 2.25mL of DNA to 0.25mL of DNA) (2) a
constant concentration of wt-NS1 and (3) ß-Gal as a control. 24 hours post-transfection, total
cells extracts were collected, processed, and analyzed by western blot. The results obtained,
indicate the percentage of SUMOylated NS1 produced when we use the wt-ASL. In addition, as
clearly as clearly seen in Fig. 9 panel A (lanes 4 to 7) there is an optimal amount of the ASL
needed to SUMOylate NS1 because after certain concentration the stability of the protein
appears to be affected due to hyperSUMOylation. Where we conclude that there is an optimal
amount of the ASL needed in order to SUMOylate NS1.
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3.3 Activity of the ASL RNA Binding Mutant
The intent of this study was to further characterize the functionality of the ASL. Here, we
tested a mutated form of the ASL that we refer to as the mut-ASL. This form of ASL is an RBD
deficient ligase and is different from the wt-ASL because as previously described wt-ASL
possesses NS1’s RBD and ED region. However, this mut-ASL is RBD deficient. For this reason,
we think that the mut-ASL probably will struggle on recruiting specific RNA targets due to its
RBD deficiency. With this tool we were studying the importance of having the RBD on the ASL
and how its absence could potentially affect the percentage of SUMOylated NS1 obtained when
used together with wt-NS1.

3.3.2 Results
In previous studies where the wt-ASL was used, it was found that there is an optimal
amount of ASL needed in order to SUMOylate NS1. With those results, our curiosity in fully
characterizing the role of the ASL we went ahead and used the same method to test the possible
effect of NS1 SUMOylation but using a mut-ASL. Thus, with the same idea in mind the same
protocol as in 3.2.2 was followed. Hek293FT cells were transfected with:

(1) different

concentrations of the mut-ASL (range 2.25mL of DNA to 0.25mL) (2) a constant concentration
of wt-NS1 and (3) ß-Gal as a control. 24 hours post-transfection total cell extracts were
collected, processed, and analyzed by western blot. The results here obtained with the mut-ASL
are consistent with those obtained in the previous studies presented with the wt-ASL (compare
the levels of SUMOylated NS1 on Fig. 9 and Fig.10). These results still suggest that there is an
optimal amount of ASL needed to SUMOylate NS1 Fig. 10 (lanes 3 to 11). In addition, it is clear
that the wt-ASL is a better subject to use than the mut-ASL, it gives large percentage of
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SUMOylated NS1 in comparison to that obtained with the mut-ASL. In addition, these results
make clear that the ability of the ASL to bind to RNA is essential to have larger percentages on
production of SUMOylated NS1.
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3.4 The ASL enhances the SUMOylation of NS1’s from different viral strains
In addition, our studies prove that the ASL is a tool functional for the NS1 protein from
Puerto Rico 1918 H1N1 influenza strain that we refer as PR8 NS1. However, we wanted to test
if this tool was specific to PR8 or if this tool was functional to use it with different types of NS1
to increase their SUMOylation. With this idea in mind we went ahead and did a set of
experiment to compare the function of the ASL with NS1’s from two different viral strains that
correspond to Wilson Smith 1933 H1N1 or WSN and the Memphis H3N2 referred as MEM. We
did a set of transfections were we used three different concentrations of the ASL with a constant
amount of (1) PR8-NS1, (2) WSN-NS1, and (3) MEM-NS1.

3.4.2 Results
To prove that the ASL was not PR8 specific we tested the ASL with two additional types
of NS1. As shown in Fig. 11 panel A, the ASL is not PR8 specific. We used PR8 Fig. 11 panel A
(lines 2-3) as a control to show the SUMOylation levels that we obtain when we use the optimal
amount of ASL to SUMOylate this NS1. And MEM and WSN were tested with the optimal
amount that was found for PR8-NS1 and two aditional amounts to determine if we could achieve
enhancement of SUMOylation by using the ASL on this two types of NS1. We then were ahead
and tested if the same effect were true for these types of NS1. When we compared the levels of
SUMOylation obtained on WSN or MEM to PR8 we found: (1) that the idea of an optimal
amount of ASL needed to SUMOylate NS1 is still true, Fig. 11 panel C is showing the
quantification of the obtained SUMOylated bands and (2) the ASL is able to enhance the
SUMOylation levels in different types of NS1 as shown in Fig. 11 panel A (lanes 4-7 for MEM
and lanes 8-11 for WSN).
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3.5 Discussion
The results here demonstrate the specificity of the ASL to NS1, we presented this by
using different lengths on the linker region that makes possible the interaction between ASL and
NS1 does not affect its specificity. However, it affects its activity decreasing the total amount of
SUMOylated NS1. Intrigued with the results, we went ahead and tested for the activity of the wtASL and mut-ASL, prompt the effect that these two forms of the ASL had on NS1, using a
constant amount of NS1 with different concentrations of both wt-ASL and mut-ASL. In this
studies we found that in both cases there is a certain proportion of NS1 and ASL in order to
efficiently SUMOylate NS1. In addition, eventhough mut-ASL shows a similar effect to enhance
NS1 SUMOylation its activity is not as strong as the one for the mut-ASL. The possible reason
of mut-ASL inability to produce higher lever of SUMOylation could be highly related to its
inability to bind to RNA makes it difficult the production of SUMOylated NS1. In addition, we
tested our ASL tool with different types of influenza strain. We tested three different NS1
proteins that correspond to two H1N1 and a H3N2 NS1. And we found that our ASL system is
functional and specific to NS1 protein.
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Chapter 4: Summary, Conclusions, and Future Directions
4.1 Summary and Conclusions
With the studies presented here we showed an overview of the functionality of the ASL
system. We conclude that the ASL has the ability to increase the SUMOylation levels of NS1. As
a result of increasing or decreasing NS1’s SUMOylation affects its ability to block the IFN
response.
In addition, when testing for the ASL activity, specificity, and functionality. We found
that the length of the linker region on the ASL affects its activity but not its specificity with NS1.
Therefore, by testing different concentrations of either wt-ASL or mut-ASL with NS1. It was
found that there is an optimal amount of ASL needed in order to SUMOylate NS1 to its
maximum level. And to prove our ligase functionality to other NS1’s we tested it with NS1’s
from different influenza stains and it shows that is effective increasing the NS1 protein
SUMOylation levels.
For this reason, here we conclude that NS1’s ability to be SUMOylated appears to affect
viral multiplication. The length of the linker affects the activity of the ASL but not its specificity
with NS1. There is an optimal level of NS1 SUMOylation that allows NS1 to achieve maximal
IFN blocking activity. And our ASL is functional with NS1’s from different viral strains.
Therefore the ASL can serve as a potential tool to effectively increase the amount of
SUMOylated NS1. The usage of this tool will open new doors to our research studies, to fully
characterize NS1’s actual role on the IFN response system and its capability to directly interact
with activating cascade receptors.
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4.2 Future Directions
Recent research studies have already shown the mechanism that the IAV NS1 protein
utilizes to shut down the host cell immune response. When the influenza virus attacks its host
cell, NS1 protein directly interacts with TRIM25 protein preventing its ubiquitination. Therefore,
the prevention of TRIM25 ubiquitination leads to the fail of RIG-I activation and this prevents
the induction of IFN. It is clearly stated that RIG-I and TRIM25 are the specific receptors
affected by NS1 protein. However, there is still little information about what gives NS1 the
ability to specifically bind to TRIM25 and prevent its ubiquitination. Due to this reason, we
suggest that SUMOylation could possibly be having an effect on NS1.
We have previously shown by using the ASL tool, that NS1 SUMOylation can be
enhanced by its use. In addition, it’s been found that NS1 SUMOylation is playing an important
role on NS1’s ability to neutralize the IFN system. Together with those results, we seek to
expand our research studies to investigate the potential effect that NS1 SUMOylation could have
on the cytoplasmic sensors involved on its recognition. Our research will lead on testing the
effects that NS1 SUMOylation when this prevents the ubiquitination of RIG-I mediated by
TRIM25. Anticipating that with the help of this information new ways to target the viral
reproduction could me implemented.
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Materials and Methods
Viruses and mammalian cell cultures
Human embryonic kidney - 293FT (Hek293FT) cells (Invitrogen Corp.) and VERO cells
are being maintained in 1X Dubelcco’s Modified Essential Medium (DMEM) supplemented
with high glucose, L-glutamine, sodium pyruvate, and 10% Fetal Bovine Serum (FBS). Hek29FT
cells are treated with 500 µg/mL of Geneticin® (Invitrogen Corp.) every time they get split. The
cells are maintained in a 37°C incubator at 5% CO2 and split every 48 h at a 1:5 ratio. Vesicular
stomatis virus – enhanced green fluorescent protein (VSV-EGFP) is stored at -80°C.
Transfections
The following plasmids were used: pcDNA5/FTO/TO, pcDNA3.1/PolIPolIIT7T7NS1,
pcDNA3.1/PolIPolII/T7T7NS1#10,

pcDNA3Pol1Pol2-T7T7NS1-K701K219A,

pcDNA3PolIPolIINS1-87-Ubc9, pcDNA3PolIPolIINS1-73-Ubc9#6, pcDNA3PolIPolIINS1-81Ubc9#1,

pcDNA3/Pol1/Pol2/T7T7NS1(1-87)(R38K41A)#4,

pcAGGS/WSN/NP,

pcAGGS/WSN/PB1,

pcDNAPolIPolIINS1R38AK41A-Ubc9,

pcAGGS/WSN/PB2,

pPOL1/WSN/PB2,
pcAGGS/WSN/PA,

pcDNA3/Pol1/Pol2/T7T7NS1(1-87)(R38K41A)#4,

pGL4.74[hRluc/TK], pISRE-Luc, pCMV/beta-galactosidase, pcDNA3/Pol1/Pol2/T7NS-WSN
#1, and pcDNA3/Pol1/Pol2/T7NS-Memphis #4. Flag-human-RIG-I-(FL) and Flag-human-RIGI(N) plasmids were provided by Dr. Daniel Perez lab. V5-TRIM25 plasmid was provided by Dr.
Jing Jung lab.
Transfections on Hek293FT cells were done in the following way: for 6-well plates at a
cell density of 0.6 X 106, 24-well plates at a cell density of 3 X 105 or 1 X 105 (cell density was
based on different experimental conditions). Following the company protocol we went ahead and
conducted liposome-mediated transfections using the plasmids mentioned above; each DNA
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combination was mixed with 26 µL (on a 6-well plate) or 8 µL (on a 24-well plate) of TransIT®LT1 reagent (Mirus Bio LLC, Madison, WI) and 250 µL (on 6-well plate) or 100 µL (on 24-well
plate) of Optimem (OptiMEm). Then we added the DNA combinations to the Hek293FT cells
and they were incubated for 24 or 48 hours in a 37°C incubator at 5% CO2.
IFN treatment for IFN assay
Supernatants from Hek293FT cells were collected 48hrs post-transfection in 1.5mL
conical screw cap tubes and stored at -80°C. Subsequently, VERO cells were plated in 24-well
plates at a density of 1 X 105 cells/mL and treated with the supernatants collected from the
transfections done on the Hek293FT cells. The supernatant treatment was applied to the VERO
cells in the following way: supernatant on the VERO cells was completely removed and 1mL of
the supernatant collected was added to each well and diluted with complete medium (1x DMEM
+ 10 % FBS) producing the following dilutions: ND (non-diluted), 1:2, 1:4, and 1:8. The cells
were incubated in a 37°C incubator at 5% CO2 for 24 hours. Finally, 24 hours post-treatment we
went ahead and conducted VSV-GFP infection in the VERO cells, method that is next described.
Infection for IFN assay
Infection was conducted on VERO cells, as previously mentioned, these cells were
treated with supernatants collected from the initial transfections done in Hek293FT. Infection
was conducted in the following way: a viral stock of VSV-GFP with viral titer of 2.13 X 107 was
used to infect VERO cells. We used a multiplicity of infection (M.O.I) of 3 of the VSV-GFP, to
dilute the virus the VSV-GFP virus was diluted with DMEM + 10% FBS. Then, the supernatant
was removed and 500µL of the dilution was added to each well. Cells were incubated for 8 hrs in
a 37°C incubator at 5% CO2.
Flow-cytometry for IFN assay
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VERO cell collection was done by trypsinization 8 hrs post-infection by adding Trypsin
EDTA 1X for 5 min and we followed by diluting the trypsin with DMEM + 10% FBS. Then, the
cells were centrifuged at 1200 rpm for 5 minutes. After centrifugation, supernatant was discarded
and the cells were fixed by re-suspension with 4% paraformaldehyde. After cell fixation samples
were analyzed by flow cytometry using the Flow Cytometer Analyzer (Cytomic FC500;
Beckman Coulter), which measured the percentage of the population of cells that were
expressing GFP (green fluorescence protein).
Confocal microscopy for IFN assay
VERO cells were incubated with supernatants collected from IFN bioassay at 37°C
incubator at 5% CO2. At 48 hours post-treatment the cells were infected with VSV-GFP reporter
virus, and 11 hours post-infection the cells were fixed with 1x PBS plus 4% paraformaldehyde
for one hour at 4°C. Then cells were washed twice with 1xPBS. After the wash they were stained
with 4’,6-diamidino-2-phenylindole (DAPI) (Molecular Probes) for 5 minutes then washed once
again two times in 1xPBS. Images were captured using an LSM 700 confocal microscope (Zeiss,
New York, NY) with a 20x objective and two lasers at 488nm (DAPI) and 488nm (GFP). Image
acquisition was performed by using ZEN 2009 software (Zeiss, New York, NY). The ZEN 2009
software was used to add pseudocolor to the images since the microscope system outfitted with a
monochromatic camera.
SDS-Page and Immunobloting
Total cell extracts were collected in 2X Sample Buffer. The samples were passes by
syringe 10 times and 20uL β-mercaptoethanol was added to make up a concentration of 10%.
Then samples were boiled for 3 min. A 10% sodium dodecyl sulfate-polyacrylamide gel
eleptrophoresis (SDS-PAGE) (made in lab) was run at 95 V for 21/2 h. Then, the proteins were
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transferred to a polyvinylidene diflouride (PVDF) ImmobilonTM-FL membrane using a tankblotting system, at 2.00 A for 120 min. The membrane was washed three times in 1 X PBS
supplemented with 1% Tween-20. Subsequently, the membrane was blocked with 1 X PBS + 1
% Tween-20 + 3 % non-fat milk for 1 hr at room temperature followed by incubation with the
primary antibody overnight at 4°C. The next day, membranes were washed three times with 1 X
PBS + 1% Tween-20, then they were incubated with secondary antibody for 1 hr. Finally,
membranes were washed three times with 1 X PBS + 1 % Tween-20 and analyzed by an
scanning system provided by Odyssey® CLx infrared imaging system (LI-COR Biosciences
Inc.).
The primary and secondary antibodies used for the immunoblot are described followed by the
desired dilutions. The primary antibodies that were used are the following: anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) monoclonal antibody (MAb) (Santa Cruz Biotechnology
Inc.) at 1:5000 dilution, anti-ubc9 rabbit MAb (Epitomics Inc.) at 1:5000 dilution, anti-SUMO1
rabbit MAb (Epitomics Inc. Burlingame, CA) at 1:5000 dilution, anti-T7 tag MAb (Novagen,
EMD Biosciences Inc., San Diego, CA), 1:5,000 dilution, anti Beta-Galactosidase (β-Gal), antiRenilla and anti-Firefly. The secondary antibodies used are the following: highly cross-absorbed
infrared dye® (IRDye®) 800CW conjugated goat anti-rabbit Immunoglobulin G (IgG), 1:20,000
dilution; and highly cross-absorbed IRDye® 680LT conjugated goat anti-rabbit IgG, 1:20,000
dilution (all IRDye® conjugated secondary antibodies were from LI-COR Biosciences Inc.).

38	
  

References
1. Acheson, Nicholas H. Fundamentals of molecular virology. 3rd Ed. 2007, New Jersey:
John Wiley & Sons, Inc.
2. Baum A, Garcia-Sastre A. 2011. Differential recognition of viral RNA by RIG-I.
Virulence. 2(2):166-169
3. Bekes M, Drag M. 2012. Trojan Horse Strategies Used by Pathogens to Influence the
Small Ubiquitin-Like Modifier (SUMO) System of Host Eukaryotic Cell. J Innate Immun.
4. Boehm U, Klamp T, Groot M, Howard JC. 1997. Cellular responses to interferongamma. Annu Rev Immunol. 15:749-95.
5. Boulo S, Akaru H, et al. 2007. Nuclear traffic of incluenza virus proteins and
ribonucleoprotein complexes. Virus Res. 124(1-2):12-21.
6. Drag M, Salvesen GS. 2008. DeSUMOylating Enzymes – SENPs. Life. 60(11):734-742.
7. Flint SJ, Enquist LW, et al. Principles of Virology : molecular biology, pathogenesis,
and control of animal viruses. 2nd Ed. 2004, Washington, DC: ASM Press.
8. Fukuyama S, Kawaoka Y. 2011. The pathogenesis of influenza virus infections: the
contribution of virus and host factors. Immunology. 23(4):481-486.
9. Gack MU, Albrecht RA, Urano T, et al. 2009. Influenza A Virus NS1 Targets the
Ubiquitin Ligase TRIM25 to Evade Recognition by the Host Viral RNA Sensor RIG-I.
Cell Host & Microbe. 5:439-449.
10. Gack MU, Shin YC, Joo CH, et al. 2007. TRIM25 RING-finger E3 ubiquitin ligase is
essential for RIG-I-mediated antiviral activity. Nature. 445, 916-920.
11. Hale BG, Randall RE, Ortin J, Jackson D. 2008. The multifunctional NS1 protein of
influenza A viruses. J Virol 89:2359-76.
12. Hornung V, Ellegast J, Kim S, et al. 2006. 5’-Triphosphate RNA is the Ligand for RIGI. Science. 314, 5801:994-97.
13. Ireton R and Gale M. 2011. RIG-I Like Receptors in Antiviral Immunity and
Therapeutic Applications. Viruses. 3:906-19.
14. Isaacson MK, Ploegh H. 2009. Ubiquitination, Ubiquitin-like Modifiers, and
Deubiquitination in Viral Infection. Cell. 5:559-570
15. Itzstein Mark von. 2007. The war against influenza: discovery and development of
sialidase inhibitors. Nature Reviwes Drug Discovery. 6:967-974.
16. Jones A, Jones R. 2011. Influenza Infection Risk and Predominant Exposure Route:
Uncertainty Analysis. Risk Analysis. 31:1622-1631.
17. Ke Xu, Christoph Klenk, Bin Liu, Bjoern Keiner, Jinke Cheng, Bo-Jian Zheng, Li
Li, et al. 2011. Modification of Nonstructural Protein 1 of Influenza A Virus by SUMO1.
J Virol 85(2):1086-89.
18. Knipscheer P, Flotho A, Klug H, Olsen JV, van Dijk WJ, Fish A, Johnson ES, Mann
M, Sixma TK 2008. Ubc9 sumoylation regulates SUMO target discrimination. Mol Cell.
8;31(3):371-82.
19. Kowalinski E, Lunardi T, McCarthy A, et al. 2011. Receptor RIG-I by Viral RNA.
Cell. 147:423-35.
20. Krieg AM, Vollmer Jorg. 2007. Toll-like receptors 7, 8, and 9: liking innate immunity
to autoimmunity. Immunological Reviews. 220:251-69.
39	
  

21. Melchior F and Geiss-Friedlander R. 2007. Concepts in SUMOylation: a decade on.
Molecular Cell Biology. 947-956.
22. Pal S, Rosas JM, Rosas-Acosta G. 2010. Identification of the non-structural influenza A
viral protein NS1A as a bona fide target of the Small Ubiquitin-like MOdifier by the use
of dicistronic expression constructs. J Virol 163(2):498-504.
23. Rajsbaum R, Albrecht RA, Wang MK, Maharaj NP, et al. 2012. Species-Specific
Inhibition of RIG-I Ubiquitination and IFN Induction by the Influenza A Virus NS1
Protein. PLOS Pathogens. 8(11);1-16.
24. Rehwinkel J, Tan C, Goubau D, et al. 2010. RIG-I Detects Viral Geznomic RNA during
Negative-Strand RNA Virus Infection. Cell. 140:397-408
25. Salomon R, Webster R. 2010. The Influenza Virus Enigma. Cell. 136(3):402-410.
26. Samji T. 2009. Influenza A: Understanding the Viral Life Cycle. Yale Journal of Biology
and Medicine. 153-159.
27. Santos A, Pal S, et al. 2013. SUMOylation Affects the Interferon Blocking Activity of the
Influenza A Nonstructural Protein NS1 without Affecting Its Stability or Cellular
Localization. Journal of Virology. 87:10:5602-20.
28. Wilson VG, Rangasamy D. 2001. Viral interaction with the host cell SUMOylation
system. Virus Res. 4;81(1-2):17-27.

40	
  

Glossary
-RNA – negative strand RNA
-ssRNA – negative sense single stranded ribonucleic acid
+RNA – positive sense RNA
AOS1-UBA2 – Protein complex that form SUMO activating enzyme E1 also known as SAE1SAE2
ASL- Artificial SUMO Ligase
ATF-2 – Activating transcription factor 2
ATP – Adenosine triphosphate
C-terminal – Carboxy-terminus
CARD – caspase recruitment domain
Cys – Cysteine
DMEM – Dubelcco’s Modified Essential Medium
dsRNA – double stranded ribonucleic acid
e.g. – example given
E1 – Activating enzyme
E2 – Conjugating enzyme
E3 – Protein ligase
ED – Effector Domain
EDTA – Ethylenediaminetetraacetic acid
EGFP – Enhanced Green Fluorescent Protein
FBS – Fetal Bovine Serum
FL – Full length
Fluc – Firefly Luciferase
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase
Glu –Glutamic acid
Gly- Glycine acid
H+ – Hydrogen ions
HA – Hemagglutininn
Hek293FT cells – Human embryonic kidney 293 FT cells
i.e. – in effect
IAV – Influenza A virus
IFN – Interferon
IFN α/ß – Type I Interferon
IFN γ - Type II Interferon
IFNs – Interferons
IgG – Immonoglobulin G
IPS-1 – Interferon-beta promoter stimulator protein 1
IRDye – Infrared dye
IRF3 – interferon regulatory factor 3
ISG15 – Interferon Stimulated Gene 15
ISGs – interferon-stimulated genes
K – Lys – Lysine
kD – KiloDalton
LAR II – Luciferase Assay Reagent II
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Leu –Leucine acid
LI-COR – Lighting correlation
Lys - Lysine
M1 – Matrix 1
M2 – Matrix 2
MAb – Monoclonal antibody
MAVS – Mitochondrial antiviral-signaling protein
mRNA – Messenger ribonucleic acid
M.O.I – Multiplicity of infection
mut-ASL – NS1 with infuse ubc9 RBD deficient
N-terminal – Amino terminus
NA – Neuraminidase
ND – Non-diluted
NEP – Nuclear export protein
NF-κB – nuclear factor kappa-light-chain-enhancer of activated B cells
Non-SUMO-NS1 – Non-SUMOylatable for of NS1
Non-SUMOylatable NS1 – NS1-KYOAK219A
NP – Nucleoprotein
NS1 – Non-structural protein 1
NS2 – Non-structural protein 2
OAS – 2'-5'oligoadenylate synthetase
PA – Polymerase acidic protein
PAMPs – pathogen-associated molecular patterns
PB1 – Polymerase basic protein 1
PB1-F2 – polymerase basic protein 1 – F2
PB2 – Polymerase basic protein 2
PBS – Phosphate Buffer Basic Solution
PKR – Protein kinase R
PLB – Passive Lysis Buffer
POLI – RNA Polymerase I
POLII – RNA Polymerase II
PRRs – pattern recognition receptors
PVDF – Polyvinylidene diflouride
RBD – RNA-Binding Domain
RdRp – RNA dependent RNA polymerase
RIG-I – retinoic acid-inducible gene 1
RLRs – RIG-I-like receptors
Rluc – Renilla Luciferase
RNA – Ribonucleic acid
SAE1-SAE2 – Protein complex that form SUMO activating enzyme E1 also known as SAE1SAE2
SDS-PAGE - Sodium dodecyl sulfate-polyacrylamide gel eleptrophoresis
SENP – Sentrin Specific Protease
SUMO – Small Ubiquitin-Like Modifier
T cells – Thymus-derived cells
Thr –Threonine acid
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TLRs – toll-like receptors
TRIM25 – Tripartite motif 25
Ub – ubiquitin
UBL – Ubiquitin-like protein
Ulp1 – Ubl-specific protease 1
Ulp2 – Ubl-specific protease 2
VERO cells – Kidney epithelial cells extracted from an African green monkey
VISA – Virus induced signaling adapter
vRNA – viral RNA
vRNP – Viral Ribonucleoprotein
VSV – Vesicular Stomatis Virus
WHO – World Health Organization
wt-ASL – NS1 with infuse ubc9
wt-NS1 – NS1 (1-87) ubc9
β-Gal – Beta-Galactosidase
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